AstraZeneca revenue advances 7% in Q3 to $16.21 billion

AstraZeneca (NASDAQ:AZN) reported third-quarter 2026 revenue of $16.21 billion, up 7% at constant exchange rates, while core earnings per share increased 19% to $2.79.

The results exceeded analyst expectations of approximately $15.99 billion in revenue and $2.59 in core EPS, while reported earnings per share increased 26% to $2.02.

For the nine months ended September 30, revenue reached $46.88 billion, up 7% at constant exchange rates, while core operating profit increased 14% to $16.4 billion and core EPS rose 14% to $8.00.

AstraZeneca announced a restructuring programme targeting $1.5 billion in annual pre-tax savings, with up to $2 billion in one-time charges, and said most of the programme should be completed by the end of 2029.

The company reaffirmed its 2026 guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth, while management said the savings would support investment in its drug development pipeline.

Meanwhile, oncology generated $21.89 billion in nine-month revenue, up 16% at constant exchange rates, while Rare Disease revenue increased 11% to $7.54 billion, helping offset declines in other pharmaceutical categories.